|
|
Blood, 1 September 2006, Vol. 108, No. 5, pp. 1478-1484.
Prepublished online as a Blood First Edition Paper on April 20, 2006; DOI 10.1182/blood-2006-02-001495.
 Previous Article | Next Article 
Submitted February 7, 2006
Accepted April 7, 2006
Survival advantage from Imatinib compared to the
combination Interferon- plus Cytarabine in chronic
phase CML: historical comparison between two phase III
trials
Lydia Roy, Joelle Guilhot, Tillmann Krahnke, Agnes Guerci-Bresler, Brian J Druker, Richard A Larson, Stephen G O'Brien, Charlene So, Giorgio Massimini, and Francois Guilhot*
1 Department of Oncology-Hematology and Cell Therapy, EA 3805 and Clinical Research Centre, CHU La M
Novartis Pharma AG, Basel, Switzerland
Department of Hematology, CHU Brabois, Vandoeuvre les Nancy, France
Oregon Health Science University Cancer Institute, Portland, OR, USA
University of Chicago, Chicago, IL, USA
University of Newcastle, Newcastle, United Kingdom
Centre Hospitalier Universitaire De Poitiers
* Corresponding author; email: f.guilhot{at}chu-poitiers.fr.
In the multinational IRIS study comparing imatinib to
interferon plus cytarabine (IFN/AraC) in patients with
newly diagnosed chronic-phase chronic myelogenous
leukaemia (CP CML), imatinib demonstrated significantly
higher rates of complete cytogenetic responses (CCyR)
and improved progression free survival (PFS). However,
because of a high early cross over rate to imatinib,
survival benefit was not assessable. Here we report the
result of a study comparing long term outcome of
patients included in two prospective randomized trials:
551 patients assigned to imatinib in the IRIS trial from
2000 to 2001 and 325 patients who received the
combination IFN/AraC in the CML91 trial between 1991 and
1996 before imatinib was available. With a follow-up of
42 months for both groups of patients, estimated CCyR,
survival free of transformation and overall survival
were significantly higher with imatinib compared with
IFN/AraC (P < .0001, P = .004, and P < .0001
respectively). Improved overall survival was also
confirmed within different Sokal prognostic risk groups.
Interestingly, among all patients who achieved major
cytogenetic response or CCyR at 12 months, the survival
rate was similar irrespective of their treatment. In
conclusion, within the limitation of this historical
comparison, there is a survival advantage from first
line therapy with imatinib over IFN/AraC.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Baccarani, M. Dreyling, and On behalf of the ESMO Guidelines Working Group
Chronic myelogenous leukemia: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc.,
May 1, 2009;
20(suppl_4):
iv105 - iv107.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Tam, H. Kantarjian, G. Garcia-Manero, G. Borthakur, S. O'Brien, F. Ravandi, J. Shan, and J. Cortes
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
Blood,
August 1, 2008;
112(3):
516 - 518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. de Lavallade, J. F. Apperley, J. S. Khorashad, D. Milojkovic, A. G. Reid, M. Bua, R. Szydlo, E. Olavarria, J. Kaeda, J. M. Goldman, et al.
Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis
J. Clin. Oncol.,
July 10, 2008;
26(20):
3358 - 3363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Michor
Mathematical Models of Cancer Stem Cells
J. Clin. Oncol.,
June 10, 2008;
26(17):
2854 - 2861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ramirez and J. F. DiPersio
Therapy Options in Imatinib Failures
Oncologist,
April 1, 2008;
13(4):
424 - 434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Laudadio, M. W.N. Deininger, M. J. Mauro, B. J. Druker, and R. D. Press
An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Chronic Myeloid Leukemia Patients Undergoing Kinase Inhibitor Therapy
J. Mol. Diagn.,
March 1, 2008;
10(2):
177 - 180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hochhaus, B. Druker, C. Sawyers, F. Guilhot, C. A. Schiffer, J. Cortes, D. W. Niederwieser, C. Gambacorti-Passerini, R. M. Stone, J. Goldman, et al.
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-{alpha} treatment
Blood,
February 1, 2008;
111(3):
1039 - 1043.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Press, C. Galderisi, R. Yang, C. Rempfer, S. G. Willis, M. J. Mauro, B. J. Druker, and M. W.N. Deininger
A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response
Clin. Cancer Res.,
October 15, 2007;
13(20):
6136 - 6143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Goldman
How I treat chronic myeloid leukemia in the imatinib era
Blood,
October 15, 2007;
110(8):
2828 - 2837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Rodrigues and M. Sattler
Chronic Myelogenous Leukemia Progenitors Display a Genetically Unstable Personality
J Natl Cancer Inst,
May 2, 2007;
99(9):
662 - 663.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Kantarjian, F. Giles, A. Quintas-Cardama, and J. Cortes
Important Therapeutic Targets in Chronic Myelogenous Leukemia
Clin. Cancer Res.,
February 15, 2007;
13(4):
1089 - 1097.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Druker, F. Guilhot, S. G. O'Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M. W.N. Deininger, R. T. Silver, J. M. Goldman, R. M. Stone, et al.
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
N. Engl. J. Med.,
December 7, 2006;
355(23):
2408 - 2417.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Kantarjian, M. Talpaz, S. O'Brien, D. Jones, F. Giles, G. Garcia-Manero, S. Faderl, F. Ravandi, M. B. Rios, J. Shan, et al.
Survival benefit with imatinib mesylate versus interferon-{alpha}-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia
Blood,
September 15, 2006;
108(6):
1835 - 1840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
